All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naproxen Sodium,Sumatriptan
Therapeutic Area: Neurology Product Name: Suvexx
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: Undisclosed Upfront Cash: $2.0 million
Deal Type: Partnership December 21, 2020
Details:
Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estonia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizaport
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Exeltis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 27, 2020
Details:
Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries Ltd.
Deal Size: Undisclosed Upfront Cash: $3.9 million
Deal Type: Licensing Agreement July 28, 2020
Details:
The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
IntelGenx recently received from the U.S. FDA Complete Response Letter regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm®.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
